Literature DB >> 23887293

The estimation of tumor cell percentage for molecular testing by pathologists is not accurate.

Alexander J J Smits1, J Alain Kummer2, Peter C de Bruin2, Mijke Bol3, Jan G van den Tweel3, Kees A Seldenrijk2, Stefan M Willems3, G Johan A Offerhaus3, Roel A de Weger3, Paul J van Diest3, Aryan Vink3.   

Abstract

Molecular pathology is becoming more and more important in present day pathology. A major challenge for any molecular test is its ability to reliably detect mutations in samples consisting of mixtures of tumor cells and normal cells, especially when the tumor content is low. The minimum percentage of tumor cells required to detect genetic abnormalities is a major variable. Information on tumor cell percentage is essential for a correct interpretation of the result. In daily practice, the percentage of tumor cells is estimated by pathologists on hematoxylin and eosin (H&amp;E)-stained slides, the reliability of which has been questioned. This study aimed to determine the reliability of estimated tumor cell percentages in tissue samples by pathologists. On 47 H&amp;E-stained slides of lung tumors a tumor area was marked. The percentage of tumor cells within this area was estimated independently by nine pathologists, using categories of 0-5%, 6-10%, 11-20%, 21-30%, and so on, until 91-100%. As gold standard, the percentage of tumor cells was counted manually. On average, the range between the lowest and the highest estimate per sample was 6.3 categories. In 33% of estimates, the deviation from the gold standard was at least three categories. The mean absolute deviation was 2.0 categories (range between observers 1.5-3.1 categories). There was a significant difference between the observers (P<0.001). If 20% of tumor cells were considered the lower limit to detect a mutation, samples with an insufficient tumor cell percentage (<20%) would have been estimated to contain enough tumor cells in 27/72 (38%) observations, possibly causing false negative results. In conclusion, estimates of tumor cell percentages on H&amp;E-stained slides are not accurate, which could result in misinterpretation of test results. Reliability could possibly be improved by using a training set with feedback.

Entities:  

Mesh:

Year:  2013        PMID: 23887293     DOI: 10.1038/modpathol.2013.134

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  54 in total

1.  Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data.

Authors:  Catherine Grasso; Timothy Butler; Katherine Rhodes; Michael Quist; Tanaya L Neff; Stephen Moore; Scott A Tomlins; Erica Reinig; Carol Beadling; Mark Andersen; Christopher L Corless
Journal:  J Mol Diagn       Date:  2014-11-07       Impact factor: 5.568

2.  Is tumor cellularity in primary invasive breast carcinoma of prognostic significance?

Authors:  Emily S Reisenbichler; William Dupont; W Dale Plummer; Omar Hameed
Journal:  Virchows Arch       Date:  2017-04-19       Impact factor: 4.064

Review 3.  Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Authors:  Lawrence J Jennings; Maria E Arcila; Christopher Corless; Suzanne Kamel-Reid; Ira M Lubin; John Pfeifer; Robyn L Temple-Smolkin; Karl V Voelkerding; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-03-21       Impact factor: 5.568

4.  Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification.

Authors:  Robert L Ferris; Jérôme Galon
Journal:  J Natl Cancer Inst       Date:  2016-05-12       Impact factor: 13.506

5.  Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.

Authors:  Jonathan C Dudley; Grzegorz T Gurda; Li-Hui Tseng; Derek A Anderson; Guoli Chen; Janis M Taube; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

6.  Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment.

Authors:  Benoît Lhermitte; Caroline Egele; Noëlle Weingertner; Damien Ambrosetti; Bérengère Dadone; Valérie Kubiniek; Fanny Burel-Vandenbos; John Coyne; Jean-François Michiels; Marie-Pierre Chenard; Etienne Rouleau; Jean-Christophe Sabourin; Jean-Pierre Bellocq
Journal:  Virchows Arch       Date:  2016-11-16       Impact factor: 4.064

7.  CHoMP: a chemoenzymatic histology method using clickable probes.

Authors:  Sara H Rouhanifard; Aimé López-Aguilar; Peng Wu
Journal:  Chembiochem       Date:  2014-11-17       Impact factor: 3.164

8.  Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.

Authors:  Kevin E Fisher; Linsheng Zhang; Jason Wang; Geoffrey H Smith; Scott Newman; Thomas M Schneider; Rathi N Pillai; Ragini R Kudchadkar; Taofeek K Owonikoko; Suresh S Ramalingam; David H Lawson; Keith A Delman; Bassel F El-Rayes; Malania M Wilson; H Clifford Sullivan; Annie S Morrison; Serdar Balci; N Volkan Adsay; Anthony A Gal; Gabriel L Sica; Debra F Saxe; Karen P Mann; Charles E Hill; Fadlo R Khuri; Michael R Rossi
Journal:  J Mol Diagn       Date:  2016-01-20       Impact factor: 5.568

9.  Automatic cellularity assessment from post-treated breast surgical specimens.

Authors:  Mohammad Peikari; Sherine Salama; Sharon Nofech-Mozes; Anne L Martel
Journal:  Cytometry A       Date:  2017-10-04       Impact factor: 4.355

10.  Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors.

Authors:  Katherine Geiersbach; Nils Adey; Noah Welker; Danielle Elsberry; Elisabeth Malmberg; Sumie Edwards; Erinn Downs-Kelly; Mohamed Salama; Mary Bronner
Journal:  Cancer Genet       Date:  2015-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.